We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-11.36%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$212M
AUM Growth
-$128M
Cap. Flow
-$78.2M
Cap. Flow %
-36.84%
Top 10 Hldgs %
61.58%
Holding
34
New
4
Increased
5
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$10.1M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$9.34M
3
UPB
Upstream Bio Inc
UPB
+$6.7M
4
KALV
KalVista Pharmaceuticals
KALV
+$5.05M
5
MREO
Mereo BioPharma
MREO
+$4.52M

Top Sells

Rank Stock Value
1
NGNE icon
Neurogene
NGNE
+$20.9M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$11.9M
3
PLRX icon
Pliant Therapeutics
PLRX
+$11.7M
4
ACLX
Arcellx
ACLX
+$8.35M
5
ORKA
Oruka Therapeutics
ORKA
+$6.97M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.6B
$17.7M 8.32%
505,007
+250,007
+98% +$9.34M
CYTK icon
2
Cytokinetics
CYTK
$10.5B
$16.9M 7.98%
360,000
+44,000
+14% +$2.29M
KALV
3
DELISTED
KalVista Pharmaceuticals
KALV
$15.1M 7.13%
1,787,003
+487,500
+38% +$5.05M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.09B
$14.4M 6.78%
750,000
– –
PLRX icon
5
Pliant Therapeutics
PLRX
$64.4M
$13.9M 6.55%
1,055,000
-855,121
-45% -$11.7M
ABVX
6
Abivax
ABVX
$10.9B
$12.1M 5.69%
1,648,523
-480,250
-23% -$4.42M
DVAX
7
DELISTED
Dynavax Technologies
DVAX
$11M 5.18%
860,000
-466,234
-35% -$5.64M
NGNE icon
8
Neurogene
NGNE
$656M
$10.1M 4.77%
442,761
-561,530
-56% -$20.9M
EOLS icon
9
Evolus
EOLS
$385M
$9.89M 4.66%
895,524
-274,476
-23% -$3.86M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.06B
$9.61M 4.53%
+245,272
New +$10.1M
UNCY icon
11
Unicycive Therapeutics
UNCY
$137M
$8.72M 4.11%
1,098,000
+242,100
+28% +$1.34M
ZURA icon
12
Zura Bio
ZURA
$516M
$7.93M 3.73%
3,170,194
-93,478
-3% -$333K
AUTL
13
Autolus Therapeutics
AUTL
$397M
$7.07M 3.33%
3,009,392
+197,437
+7% +$667K
JSPR icon
14
Jasper Therapeutics
JSPR
$21M
$6.89M 3.25%
322,380
– –
MRUS
15
DELISTED
Merus
MRUS
$6.65M 3.13%
158,092
-91,908
-37% -$4.41M
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.84B
$6M 2.83%
275,000
– –
BBOT
17
BridgeBio Oncology
BBOT
$648M
$5.25M 2.47%
500,000
– –
UPB
18
Upstream Bio Inc
UPB
$343M
$4.93M 2.32%
+300,000
New +$6.7M
CNTX icon
19
Context Therapeutics
CNTX
$55.1M
$4.92M 2.32%
4,683,711
-2,251,271
-32% -$3.9M
VYGR icon
20
Voyager Therapeutics
VYGR
$183M
$4.69M 2.21%
826,751
-133,202
-14% -$859K
ORKA
21
Oruka Therapeutics
ORKA
$5.82B
$4.44M 2.09%
228,803
-285,856
-56% -$6.97M
MREO
22
Mereo BioPharma
MREO
$54.7M
$4.03M 1.9%
+1,150,000
New +$4.52M
RZLT icon
23
Rezolute
RZLT
$454M
$3.05M 1.44%
+621,894
New +$3.13M
PMN icon
24
ProMIS Neurosciences
PMN
$123M
$2.51M 1.18%
105,805
-5,823
-5% -$145K
OPTN
25
DELISTED
OptiNose
OPTN
$2.47M 1.17%
370,269
-487,140
-57% -$4.29M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Great Point Partners held 34 positions worth $212M, down 38% from $340M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Great Point Partners withdrew a net $78.2M in Q4 2024, closing 8 positions and reducing 13 holdings. Its most notable exit was Olema Pharmaceuticals, an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Xenon Pharmaceuticals worth $9.61M.

  • Great Point Partners's largest Q4 2024 buy was Xenon Pharmaceuticals: 245,272 shares worth $9.61M.
  • Great Point Partners added most to Ionis Pharmaceuticals in Q4 2024, an estimated $9.34M increase.
  • Great Point Partners's biggest Q4 2024 reduction was Neurogene, cutting an estimated $20.9M.
  • Great Point Partners fully exited Olema Pharmaceuticals in Q4 2024, selling an estimated $11.9M.
  • Great Point Partners's ten largest holdings make up 62% of its $212M portfolio in Q4 2024.
  • Great Point Partners opened 4 new positions and closed 8 in Q4 2024.
  • Great Point Partners's portfolio value fell 38% quarter-over-quarter to $212M.

Based on Great Point Partners's 13F filing for Q4 2024, filed 14 Feb 2025.